DNA Plasmids for Retroviral CAR TCR Manufacturing
Summary
USPTO published patent application US20260108629A1 filed by Edward Liao on August 13, 2025, covering DNA molecules such as transfer plasmids useful for manufacturing packaged retroviral vectors encoding therapeutic proteins including chimeric antigen receptors (CARs) and T cell receptors (TCRs). The application specifies that the encoded retroviral transcript includes a transgene, an EF1α promoter without the EF1α intron, operably linked to the transgene, and a Rev response element (RRE).
“The present disclosure provides DNA molecules, such as transfer plasmids, useful for manufacturing packaged retroviral vectors encoding a therapeutic protein such as chimeric antigen receptors (CARs) and T cell receptors (TCRs).”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108629A1 for DNA molecules and transfer plasmids designed for manufacturing packaged retroviral vectors encoding therapeutic CAR and TCR proteins. The application covers genetic constructs featuring an EF1α promoter without the EF1α intron, operably linked to a transgene, and including a Rev response element (RRE).
Biopharmaceutical and cell therapy companies developing CAR-T or TCR-based therapeutics should review this application to assess potential freedom-to-operate considerations for their plasmid-based vector manufacturing processes. The patent claims specific promoter/transgene configurations and RRE elements relevant to retroviral vector production for gene therapy applications.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
VECTORS FOR PRODUCTION OF THERAPEUTIC CONSTRUCTS
Application US20260108629A1 Kind: A1 Apr 23, 2026
Inventors
Edward Liao
Abstract
The present disclosure provides DNA molecules, such as transfer plasmids, useful for manufacturing packaged retroviral vectors encoding a therapeutic protein such as chimeric antigen receptors (CARs) and T cell receptors (TCRs). The encoded retroviral transcript in the DNA molecule includes a transgene, an elongation factor 1-alpha 1 (EF1α) promoter, without the EF1α intron, operably linked to the transgene and a Rev response element (RRE).
CPC Classifications
A61K 48/005 A61K 40/31 A61K 40/4215 C07K 14/4705 C07K 14/7051 C07K 14/70521 C07K 14/70578 C07K 16/2878 C12N 15/86 A61K 2239/13 A61K 2239/21 C07K 2319/02 C12N 2740/15043 C12N 2740/15051 C12N 2830/48
Filing Date
2025-08-13
Application No.
19298435
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.